MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.6800
-0.0300 (-1.75%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.7100
Open1.7100
Bid1.68 x 1200
Ask1.72 x 1400
Day's Range1.6600 - 1.7450
52 Week Range0.9800 - 4.0500
Volume1,318,152
Avg. Volume2,256,269
Market Cap268.125M
Beta (3Y Monthly)2.88
PE Ratio (TTM)N/A
EPS (TTM)-0.83
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research5 days ago

    MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target

    Zacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. MannKind Corporation (MNKD) was founded in the early 2000’s by the late Alfred Mann, a physicist by training, Mann was a pioneer in several fields including aerospace, electronics and medical devices. Among his successes prior to MannKind was development of the first rechargeable pacemaker and MiniMed, a revolutionary miniaturized insulin pump that was sold to Medtronic in 2001 for more than $3B.

  • ACCESSWIRE6 days ago

    Biotech Stocks Beating the Market

    HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Here are several biotech plays to pay close attention to in the coming sessions. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), MannKind ...

  • GlobeNewswire19 days ago

    MannKind Appoints Christine Mundkur to its Board of Directors

    MannKind Corporation (MNKD) today announced that Christine Mundkur has joined its Board of Directors, effective November 27, 2018.  Ms. Mundkur will also serve as a member of the Audit Committee of the Board. Ms. Mundkur brings 25 years of experience in the pharmaceutical industry to the MannKind Board. “Christine brings a tremendous wealth of experience to our board of directors,” said Kent Kresa, Chairman of the Board of MannKind Corporation.

  • Analysts: Why United Therapeutics has had a streak of licensing deals
    American City Business Journals19 days ago

    Analysts: Why United Therapeutics has had a streak of licensing deals

    United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of MNKD earnings conference call or presentation 1-Nov-18 1:00pm GMT

    Q3 2018 MannKind Corp Earnings Call

  • Associated Presslast month

    MannKind: 3Q Earnings Snapshot

    On a per-share basis, the Westlake Village, California-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $4.5 million in the period. The company's shares closed ...

  • GlobeNewswirelast month

    MannKind Corporation Reports 2018 Third Quarter Financial Results

    Conference Call to Begin Today at 9:00 AM ET Executed license and collaboration agreement with United Therapeutics for up to $95 million in upfront and milestone payments plus.

  • United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript

    UTHR earnings call for the period ending September 30, 2018.

  • GlobeNewswire2 months ago

    MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018

    WESTLAKE VILLAGE, Calif., Oct. 25, 2018 -- MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 third quarter and year-to-date financial results.

  • GlobeNewswire2 months ago

    Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Altimmune and MannKind

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...

  • Why MannKind Corp. Soared 16.4% Tuesday
    Motley Fool2 months ago

    Why MannKind Corp. Soared 16.4% Tuesday

    The company has completed its planned transaction with United Therapeutics.

  • GlobeNewswire2 months ago

    United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement

    United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.  MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

  • PR Newswire2 months ago

    United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement

    RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.  MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.

  • GlobeNewswire2 months ago

    Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, was recently awarded top honors for its first Afrezza® TV commercial, “Unexpected Moments,” at the Medical Marketing & Media (MM&M) awards ceremony last week. The company worked with precisioneffect, a Boston-based healthcare advertising agency, to produce the advertisement. “Managing mealtime control is crucial in order to help individuals living with diabetes optimize their outcomes,” said Michael Castagna, CEO of MannKind Corporation.

  • Here's What Sent MannKind Corporation Soaring 66.4% in September
    Motley Fool2 months ago

    Here's What Sent MannKind Corporation Soaring 66.4% in September

    A new collaboration agreement breathed life into the troubled manufacturer of inhaled insulin powder.

  • GlobeNewswire2 months ago

    MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, presented data from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with type 1 diabetes on multiple daily injections) at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. The STAT study is the first randomized, controlled study to assess diabetes control using continuous glucose monitoring (CGM) and Afrezza® in individuals with type 1 diabetes.

  • GlobeNewswire2 months ago

    MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes

    MannKind Corporation (MNKD), announced that it presented new scientific data in an oral and poster presentation at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. PS 097) both took place Tuesday, October 2, 2018.

  • MannKind Stock History
    Motley Fool3 months ago

    MannKind Stock History

    Here's the full story of how this biopharma got to where it is today.

  • GlobeNewswire3 months ago

    MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients

    MannKind Corporation (MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in pediatric patients is now open for enrollment. The first group of individuals participating in the ongoing pediatric study of Afrezza, which included adolescents with type 1 diabetes aged 13-17 years old, was recently completed. The study findings to date support that the single‑dose pharmacokinetic (PK) profile of insulin levels for this age group is consistent with patterns seen in adult patients.  In addition, dosing over a one‑month period demonstrated a safety profile consistent with that observed in adults.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of MNKD earnings conference call or presentation 2-Aug-18 9:00pm GMT

    Q2 2018 MannKind Corp Earnings Call

  • Implied Volatility Surging for MannKind (MNKD) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for MannKind (MNKD) Stock Options

    MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.

  • ACCESSWIRE3 months ago

    Mannkind Afrezza Sales Have Doubled and Treprostinil is Getting Some Traction

    NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. On September 4th, MannKind announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. MNKD doubled its market share over the past year as a result of its commercialization efforts and are excited about its new Afrezza clinical data being released throughout 2018.

  • Motley Fool3 months ago

    Is MannKind Corporation Stock a Buy?

    A new collaboration is funneling tens of millions of dollars onto the diabetes company’s balance sheet.